Traditionally, the BBB has been considered to be a major hindrance to the use of chemotherapy for brain tumors. In theory, the BBB selectively excludes many chemotherapeutic agents from the CNS, thereby creating a “safe haven” for some tumors, e.g. metastases.
This concept has been challenged 1). Regardless of the etiology, the response of most brain tumors to systemic chemotherapy is usually very modest, with a notable exception being a favorable response of oligodendrogliomas and gliomas lacking MGMT activity.
The blood brain barrier (BBB) is a highly selective permeability barrier that separates the circulating blood from the brain extracellular fluid (BECF) in the central nervous system (CNS).
The blood-brain barrier is formed by capillary endothelial cells, which are connected by tight junctions with an extremely high electrical resistance of at least 1000Ωcm-2.
The blood-brain barrier allows the passage of water, some gases, and lipid soluble molecules by passive diffusion, as well as the selective transport of molecules such as glucose and amino acids that are crucial to neural function. On the other hand, the blood-brain barrier may prevent the entry of lipophilic, potential neurotoxins by way of an active transport mechanism mediated by P-glycoprotein. Astrocytes are necessary to create the blood-brain barrier. A small number of regions in the brain, including the circumventricular organs (CVOs), do not have a blood-brain barrier.
The blood-brain barrier occurs along all capillaries and consists of tight junctions around the capillaries that do not exist in normal circulation.
Endothelial cells restrict the diffusion of microscopic objects (e.g., bacteria) and large or hydrophilic molecules into the cerebrospinal fluid (CSF), while allowing the diffusion of small hydrophobic molecules (O2, CO2, hormones).
Cells of the barrier actively transport metabolic products such as glucose across the barrier with specific proteins.
This barrier also includes a thick basement membrane and astrocytic end feet.
Drug delivery to the central nervous system (CNS) is complicated by the blood-brain barrier. As a result, many agents that are found to be potentially effective at their site of action cannot be sufficiently or effectively delivered to the CNS and therefore have been discarded and not developed further for clinical use, leaving many CNS diseases untreated. One way to overcome this obstacle is intracerebroventricular (ICV) delivery of the therapeutics directly to cerebrospinal fluid (CSF). Recent experimental and clinical findings reveal that CSF flows from the ventricles throughout the parenchyma towards the subarachnoid space also named minor CSF pathway, while earlier, it was suggested that only in pathological conditions such as hydrocephalus this form of CSF flow occurs. This transependymal flow of CSF provides a route to distribute ICV-infused drugs throughout the brain. More insight on transependymal CSF flow will direct more rational to ICV drug delivery and broaden its clinical indications in managing CNS diseases 2).
The blood-brain barrier represents a fundamental limitation in treating neurological disease because it prevents all neuropeptides from reaching the central nervous system (CNS). Currently, there is no efficient method to permanently bypass the blood-brain barrier.
Although ongoing research has yielded some potential options for future glioblastoma therapies, delivery of chemotherapy medications across the BBB remains elusive and has limited the efficacy of these medications 3).
Current strategies for enhancing the delivery of therapies across the BBB to the tumor is discussed, with a distinction made between strategies that seek to disrupt the BBB and those that aim to circumvent it in the article of Azad et al. 4).
Histological investigations have shown that disruption of the blood brain barrier (BBB) is well correlated with the degradation of collagen IV, a major component of the BBB 5). Among other basal lamina proteins, collagen IV is often degraded by metalloproteinase-9 (MMP-9)
Transmucosal delivery of glial derived neurotrophic factor (GDNF) is equivalent to direct intrastriatal injection at ameliorating the behavioral and immunohistological features of Parkinson disease in a murine model. Mucosal grafting of arachnoid defects is a technique commonly used for endoscopic skull base reconstruction and may represent a novel method to permanently bypass the blood-brain barrier 6).